Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer's disease

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Perneczky, R ^a,b   Guo, L H ^b   Kagerbauer, S M ^b   Werle, L ^b   Kurz, A ^b   Martin, J ^b   Alexopoulos, P ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer?s disease; biomarker; early diagnosis; ELISA; plasma

Indexed keywords

AMYLOID PRECURSOR PROTEIN; SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA; SOLUBLE AMYLOID PRECURSOR PROTEIN BETA; UNCLASSIFIED DRUG; ALPHA SAPP PROTEIN, HUMAN; ALPHA-SAPP PROTEIN, HUMAN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PARAMETRIC TEST; PROTEIN ANALYSIS; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; FRONTOTEMPORAL DEMENTIA; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; SECRETION (PROCESS); SOLUBILITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PSYCHIATRIC STATUS RATING SCALES; SOLUBILITY;

EID: 84873664575     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.11     Document Type: Article

References (10)

1. Zhang H, Ma Q, Zhang YW, Xu H. Proteolytic processing of Alzheimer's beta-amyloid precursor protein. J Neurochem 2012; 120: 9-21.
2. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Forstl H et al. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology 2011; 77: 35-38.
3. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2010; 15: 138-145.
4. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012; 78: 47-54.
5. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008; 49: 390-398.
6. Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. Meta-analysis of plasma amyloid-beta levels in Alzheimer's disease. J Alzheimers Dis 2011; 26: 365-375.
7. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554.
8. Wu G, Sankaranarayanan S, Hsieh SH, Simon AJ, Savage MJ. Decrease in brain soluble amyloid precursor protein beta (sAPPbeta) in Alzheimer's disease cortex. J Neurosci Res 2011; 89: 822-832.
9. Vignini A, Sartini D, Morganti S, Nanetti L, Luzzi S, Provinciali L et al. Platelet amyloid precursor protein isoform expression in Alzheimer's disease: evidence for peripheral marker. Int J Immunopathol Pharmacol 2011; 24: 529-534.
10. Jiang S, Zhang M, Ren D, Tang G, Lin S, Qian Y et al. Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2003; 118B: 99-102.